The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1b study of the anticancer stem cell agent demcizumab (DEM), pemetrexed (PEM), and carboplatin (CARBO) in pts with first-line nonsquamous NSCLC.
Mark James McKeage
Consultant or Advisory Role - OncoMed (U)
Dusan Kotasek
No relevant relationships to disclose
Ben Markman
No relevant relationships to disclose
Manuel Hidalgo
No relevant relationships to disclose
Michael Millward
No relevant relationships to disclose
Michael B. Jameson
No relevant relationships to disclose
Dean Laurence Harris
No relevant relationships to disclose
Robert J. Stagg
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
Jakob Dupont
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
Brett Gordon Maxwell Hughes
No relevant relationships to disclose